ArticleJournal of nanobiotechnology2025
Amorphous layered double hydroxide-based nano-enzyme eye drops against dry eye disease by inhibiting mitochondrial damage and pyroptosis.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An oral coral-like resveratrol nanocomplex protects against dry eye disease through ocular and systemic redox homeostasis.Bioactive materials · 2027Article
- Antioxidant and anti-senescence supramolecular complexes for managing dry eye diseases.Bioactive materials · 2026Article
- Antioxidant Nanozymes: From Rational Design to Biomedical Applications.Research (Washington, D.C.) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
Chronic inflammation serves as a prominent contributor to the progression of dry eye disease (DED). Reactive oxygen species (ROS) and the downstream NLRP3 inflammasome mediate pyroptosis, which induces the inflammatory response by releasing several inflammatory factors. Therefore, targeting pyroptosis represents a promising therapeutic strategy for controlling inflammation in DED. Herein, we report the amorphous layered double hydroxide (a-LDH)-based nano-enzyme eye drops (Needs) for DED. The a-LDH exhibits superior hydroxyl radicals (·OH) and superoxide anions (·O
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.